4.3 Article

Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: A retrospective cohort study

出版社

ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.clinre.2018.02.003

关键词

Early hepatocellular carcinoma; Microvascular invasion; HBeAg; Hepatectomy; Survival

资金

  1. Natural Science Foundation of Hubei Province [2016CFB442]

向作者/读者索取更多资源

Background: We aimed to identify the independent predictive factors of microvascular invasion (MVI) for curative resection of HCC and to investigate the impacts of MVI and HBeAg on long-term recurrence and survival after resection. Methods: The clinicopathological parameters of 237 patients with HCC with MVI who underwent hepatic resection from April 2005 to November 2010 were investigated. Clinical features and factors associated with the clinical outcomes of 386 patients with HCC without MVI were used for comparison. Results: Multivariate stepwise logistic regression analysis revealed that alpha-fetoprotein level > 100 mu g/L, positive HBeAg, and tumour size were independent prognostic factors in patients with HCC with MVI. The overall survival (OS) of patients in the HCC with MVI group was significantly poorer compared with the HCC without MVI group (P< 0.001). However, patients with HCC without MVI group exhibited a significantly better recurrence-free survival rate (RFS) (P< 0.001). While the HCC with positive HBeAg group exhibited significantly lower OS compared with the HCC with negative HBeAg group (P=0.007). Conclusions: AFP level > 100 mu g/L, positive HBeAg, and tumour size > 2 cm are independent indicators of poorer prognosis for HCC with MVI. The present study confirmed that microvascular invasion itself had a negative impact on patient survival; moreover, HBeAg was an independent risk factor influencing OS, while not RFS of patients with HCC underwent hepatectomy. It is important to predict the presence of MVI before hepatic resection to determine treatment strategies. (C) 2018 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Review Gastroenterology & Hepatology

New developments and standard of care in the management of advanced gastric cancer

Leonard Depotte, Juliette Palle, Cosimo Rasola, Chloe Broudin, Vlad-Adrian Afrasanie, Antoine Mariani, Aziz Zaanan

Summary: Advanced gastric adenocarcinoma is a disease with poor prognosis. In recent years, new drugs, such as trastuzumab for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel, and trifluridine-tipiracil, have improved patient survival. Other drugs, including monoclonal antibodies and targeted therapies, are also being evaluated.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2024)